Schrödinger, Inc. Joins Shonan Health Innovation Park Membership

Schrödinger, Inc. (Headquarters: New York, USA, hereinafter "Schrödinger") announced that it has joined the membership of the life science ecosystem "Shonan Health Innovation Park" (hereinafter "Shonan iPark").

1. Background and Purpose of Joining

Schrödinger supports the research and development of pharmaceutical companies and bio-ventures worldwide by developing and providing a software platform that integrates physics-based simulations and cutting-edge machine learning technology.

Shonan iPark is one of Japan's largest hubs for open innovation, bringing together pharmaceutical companies, startups, and academia. Through its participation in this community, Schrödinger aims to further develop and streamline the research and development of the entire ecosystem.

2. Future Activities at Shonan iPark

Following its membership, Schrödinger will contribute to the revitalization of the community through the following activities:

• Holding seminars and workshops: Sharing information on the latest drug discovery workflows and data utilization methods using computational chemistry.

• Strengthening inter-member collaboration: Utilizing Shonan iPark's network to support the exploration of new drug discovery methods through dialogue with companies and organizations with different specializations.
  
  3. Comment

Comment from Schrödinger, Inc. (Japan subsidiary)

"We are very pleased to become a member of Shonan iPark, an important hub for health innovation in Japan. As the digital utilization in drug discovery accelerates, we are committed to supporting the creation of innovative drugs originating from Japan by connecting our platform with diverse researchers at Shonan iPark."

【About Schrödinger】

Schrödinger is transforming molecular discovery with its computational platform that enables the discovery of novel and highly optimized molecules for drug discovery and materials design. Schrödinger's software platform is built on over 30 years of research and development investment and is licensed to biotechnology companies, pharmaceutical companies, industrial companies, and academic institutions worldwide. Schrödinger also leverages these platforms to advance a portfolio of collaborative research and in-house development programs. For more information, please visit https://www.schrodinger.com.